Harrow announced an expansion of its Vevye Access for All (VAFA) program, extending eligibility to patients currently prescribed Klarity-C Drops, a compounded cyclosporine 0.1% product made by Harrow’s compounding subsidiary, ImprimisRx.

Launched on March 17, 2025, the VAFA program aims to streamline access to dry eye therapy by removing common barriers such as prior authorization requirements and reimbursement delays. According to Harrow, the program offers benefits including free home delivery and a no-questions-asked money-back guarantee, while also allowing patients to choose between using their insurance or paying a low, transparent cash price.

Starting immediately, over 25,000 Klarity-C patients nationwide can switch to Vevye (cyclosporine ophthalmic solution) 0.1%, an FDA-approved treatment for the signs and symptoms of dry eye disease, for $59 per bottle–refills included. Harrow has also introduced a 5-minute prescription authorization platform to enable prescribers to easily transfer Klarity-C scripts to PhilRx, reducing administrative friction.

“We are pleased to make Vevye accessible and affordable to Klarity-C patients,” said Mark L. Baum, Chief Executive Officer of Harrow. “The secret to the success of Vevye Access for All is simple: lower costs to patients and eliminate the requirement for prescribers to endure the burden of access obstacles like prior authorizations and step therapy.”

Klarity-C prescribers looking to transition patients to Vevye can contact support at (855) 977-0975 or email at mdsupport@usephil.com.